INTRODUCTION {#sec1-1}
============

The introduction of tyrosine kinase inhibitors (TKIs) has changed the treatment options for patients with metastatic renal cell carcinoma (MRCC). The survival benefits of TKIs have been well studied, and it is recommended as a treatment option for MRCC. Knowledge and management of its side effects are essential to reduce patient\'s discomfort and avoid unnecessary treatment interruption. Using the case of a survivor of MRCC, who was treated with pazopanib for 1 year, we report the change of this patient\'s physical appearance, tumor features in computed tomography (CT) scan and the patient\'s adaptation to treatment toxicity.

CASE REPORT {#sec1-2}
===========

A 47-year-old man presented with a 1 month history of gross hematuria. CT scan showed left renal enlargement with hypoattenuating mass replacing the normal renal parenchyma without breaching renal capsule. The left renal vein was dilated and contained heterogeneously enhancing mass suggestive of tumor thrombus \[[Figure 1](#F1){ref-type="fig"}\]. The tumor thrombus extended all the way up the inferior vena cava (IVC) into the right atrium. Bone scan showed a tumor metastasis to the right tibial. He was offered left radical nephrectomy, thrombectomy that would involve sternotomy, extracorporeal circulation, and replacement inferior vena cava graft if thrombus infiltrated to IVC. He preferred not to proceed with the surgery in view of it was a major and high-risk surgery. Biopsy of the renal tumor was done and confirmed advanced left renal cell carcinoma of the clear cell type. He underwent embolization of the left lower pole segmental renal artery, intended to treat postbiopsy tumoral bleeding. He was treated with pazopanib, due to the extent of the disease.

![Contrast-enhanced computed tomography abdomen before (a and c) and 1 year following initiation of pazopanib (b and d)](UA-9-194-g001){#F1}

Two months after, the initiation of pazopanib, progressive skin discoloration, and hair depigmentation was observed \[[Figure 2](#F2){ref-type="fig"}\]. Subsequently, he complained of numbness and redness of his hands and feet. He was also noted with elevated liver enzymes and required interruption of treatment for 2 weeks.

![Photos of patient before (left) and 1 year following initiation of pazopanib (right)](UA-9-194-g002){#F2}

He was followed up with a 6 monthly CT scan. The CT scan after 1 year demonstrated in [Figure 1](#F1){ref-type="fig"}.

He returned to work and normal daily activities after 4 months of treatment. He has now been treated with pazopanib for 1 year; the side effects experienced are mainly nausea and lethargy; which are tolerable and do not require medical treatment. Surgery was offered to him again; however, he was not keen for surgery due to the positive treatment response and his tolerability to the treatment.

DISCUSSION {#sec1-3}
==========

Pazopanib is a TKI that inhibits vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptors on cancer cells and vascular endothelial cells. Hence, stopping the proliferation of tumor cells and development of tumor blood vessels.\[[@ref1]\] It is the first line treatment of MRCC with clear cell histologic component, and for patients who have received prior cytokine therapy for advanced disease, and an Eastern Cooperative Oncology Group performance status of 0 or 1.\[[@ref2]\] It is not inferior to sunitinib with comparable efficacy in terms of overall survival with fewer side effects.\[[@ref3]\]

Toxicities are class effects of the VEGF pathway that can occur at different times but do not affect all patients. Intensity varies depending on its potencies within its class group. It has unique nonhematologic adverse effects that differ from immunotherapy and cytotoxic chemotherapy. Adverse events that are reported more frequently with pazopanib include changes in hair color, hypertension, weight loss, alopecia, and increased liver enzymes.\[[@ref2]\] Sunitinib is reported with higher-grade hand-foot syndrome. The differences in safety profile reflect the selectivity of multitargeted kinases.\[[@ref3]\]

Hair depigmentation is thought to be caused by blockade of c-Kit signaling, which is important for melanocyte proliferation, differentiation, and proper pigment production.\[[@ref1]\] This toxicity has been reported in studies involving pazopanib. However, no literature reports the appearance of hair depigmentation. We show the appearance changes following pazopanib treatment. The management plan, for managing dermatological toxicities, includes dose reduction or interruption; when the side effects become intolerable or interfere with daily living activities.

There is no reported case regarding patient\'s functional status after pazopanib treatment. This patient showed good functional status along with good cancer control. This drug allowed him to return to work and carry on his normal daily life.

The CT scan after 1 year demonstrated a small left kidney with subcapsular fluid collection from the previous biopsy. The tumor bulk had significantly reduced, and corticomedullary differentiation had returned in the upper pole. Irregular renal parenchymal outline and reduced enhancement in the lower pole were likely due to previous embolization of the left lower pole segmental renal artery, which was intended to treat postbiopsy tumoral bleeding. The left renal vein tumor thrombus was smaller and less enhanced \[[Figure 2](#F2){ref-type="fig"}\]. These changes showed the effectiveness of pazopanib on controlling renal cell carcinoma. The residual normal nephron can be functional after malignant cells were controlled by pazopanib. This CT appearance is a useful guide for patients who are given a similar treatment.

CONCLUSION {#sec1-4}
==========

This patient obtained good tumor control and tolerable toxicity with pazopanib.
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